MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer

NCT01263145 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

NIH

Sponsor class

Conditions

Adult Solid Neoplasm
Recurrent Breast Carcinoma
Stage IV Breast Cancer

Interventions

DRUG: Akt Inhibitor MK2206
OTHER: Laboratory Biomarker Analysis
DRUG: Paclitaxel
OTHER: Pharmacological Study

Sponsor

National Cancer Institute (NCI)